Clinical Trial Update: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours [Phase 1]

View source ↗

Summary

A Phase 1 study of [225Ac]-FPI-2059 in adults with solid tumours was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Ewing Sarcoma
• Gastric Cancer
• Neuroendocrine Prostate Cancer
• Ntsr1 Expressing Solid Tumours
• Pancreatic Ductal Adenocarcinoma
• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• [225Ac]-FPI-2059 (FPI-2059)

Snippet

Sponsor: 3B Pharmaceuticals GmbH | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck | Phase 1 | Status: TERMINATED